Interest of D-dimer level, severity of COVID-19 and cost of management in Gabon.

Berthe A Iroungou, Arnaud Nze O, Helga M Kandet Y, Neil-Michel Longo-Pendy, Nina D Mezogho-Obame, Annicet-Clotaire Dikoumba, Guignali L Mangouka
Author Information
  1. Berthe A Iroungou: Unit�� Mixte de Recherche, Centre International de Recherches M��dicales de Franceville et le Service de Sant�� Militaire, Libreville 20404, Estuaire, Gabon. abertheamelie@gmail.com.
  2. Arnaud Nze O: AP-HP Health Economics, Research Unit, Htel Dieu Hospital, Paris 75004, Ile-de-France, France.
  3. Helga M Kandet Y: Laboratory, H��pital D'Instruction des Arm��es D'Akanda, Libreville 20404, Estuaire, Gabon.
  4. Neil-Michel Longo-Pendy: Unit�� de Recherche en ��cologie de la Sant��, Centre Interdisciplinaire de Recherches M��dicales de Franceville, Franceville 769, Gabon.
  5. Nina D Mezogho-Obame: Laboratory, H��pital D'Instruction des Arm��es Omar Bongo Ondimba, Libreville 20404, Estuaire, Gabon.
  6. Annicet-Clotaire Dikoumba: Unit�� Mixte de Recherche, Centre International de Recherches M��dicales de Franceville et le Service de Sant�� Militaire, Libreville 20404, Estuaire, Gabon.
  7. Guignali L Mangouka: Department of Medecine Polyvalente, H��pital D'Instruction des Arm��es Omar Bongo Ondimba, Libreville 20404, Estuaire, Gabon.

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) is strongly associated with an increased risk of thrombotic events, including severe outcomes such as pulmonary embolism. Elevated D-dimer levels are a critical biomarker for assessing this risk. In Gabon, early implementation of anticoagulation therapy and D-dimer testing has been crucial in managing COVID-19. This study hypothesizes that elevated D-dimer levels are linked to increased COVID-19 severity.
AIM: To determine the impact of D-dimer levels on COVID-19 severity and their role in guiding clinical decisions.
METHODS: This retrospective study analyzed COVID-19 patients admitted to two hospitals in Gabon between March 2020 and December 2023. The study included patients with confirmed COVID-19 diagnoses and available D-dimer measurements at admission. Data on demographics, clinical outcomes, D-dimer levels, and healthcare costs were collected. COVID-19 severity was classified as non-severe (outpatients) or severe (inpatients). A multivariable logistic regression model was used to assess the relationship between D-dimer levels and disease severity, with adjusted odds ratios (OR) and 95%CI.
RESULTS: A total of 3004 patients were included, with a mean age of 50.17 years, and the majority were female (53.43%). Elevated D-dimer levels were found in 65.81% of patients, and 57.21% of these experienced severe COVID-19. Univariate analysis showed that patients with elevated D-dimer levels had 3.33 times higher odds of severe COVID-19 (OR = 3.33, 95%CI: 2.84-3.92, < 0.001), and this association remained significant in the multivariable analysis, adjusted for age, sex, and year of collection. The financial analysis revealed a substantial burden, particularly for uninsured patients.
CONCLUSION: D-dimer predicts COVID-19 severity and guides treatment, but the high cost of anticoagulant therapy highlights the need for policies ensuring affordable access in resource-limited settings like Gabon.

Keywords

References

  1. J Int Med Res. 2021 Nov;49(11):3000605211059939 [PMID: 34796762]
  2. Eur Radiol. 2023 Aug;33(8):5540-5548 [PMID: 36826504]
  3. Eur Heart J. 2021 Jun 14;42(23):2260-2264 [PMID: 33486520]
  4. Cardiovasc Drugs Ther. 2021 Apr;35(2):215-229 [PMID: 33074525]
  5. Am J Emerg Med. 2021 Jan;39:173-179 [PMID: 33069541]
  6. Biomedicines. 2024 Apr 01;12(4): [PMID: 38672130]
  7. Lancet. 2020 Jun 20;395(10241):1907-1918 [PMID: 32473681]
  8. Eur Heart J. 2021 Jun 14;42(23):2270-2279 [PMID: 33448289]
  9. Thromb Res. 2021 Feb;198:34-39 [PMID: 33271421]
  10. Adv Clin Chem. 2023;114:151-223 [PMID: 37268332]
  11. Crit Care. 2020 Jun 19;24(1):364 [PMID: 32560658]
  12. Thromb Res. 2020 Dec;196:99-105 [PMID: 32853982]
  13. Nat Med. 2020 Jul;26(7):1017-1032 [PMID: 32651579]
  14. Br J Haematol. 2023 Aug;202(3):485-497 [PMID: 37202865]
  15. J Thromb Haemost. 2020 Apr;18(4):844-847 [PMID: 32073213]
  16. Int J Lab Hematol. 2021 Feb;43(1):110-115 [PMID: 32931146]
  17. Clin Chem Lab Med. 2022 Jul 14;61(5):841-850 [PMID: 35849562]
  18. Pol Arch Intern Med. 2023 Nov 29;133(11): [PMID: 37965939]
  19. Front Med (Lausanne). 2024 Jun 10;11:1399335 [PMID: 38915768]
  20. Postgrad Med. 2021 Aug;133(sup1):36-41 [PMID: 33910469]
  21. Hematol Transfus Cell Ther. 2023 Jul-Sep;45(3):306-316 [PMID: 35673599]
  22. Lancet Haematol. 2020 May;7(5):e362-e363 [PMID: 32278361]
  23. Emerg Radiol. 2021 Apr;28(2):441 [PMID: 33492529]
  24. Hematol Rep. 2023 Jun 05;15(2):358-369 [PMID: 37367086]
  25. Cardiol Rev. 2020 Nov/Dec;28(6):295-302 [PMID: 33017364]
  26. Blood. 2020 Jul 23;136(4):489-500 [PMID: 32492712]

Word Cloud

Created with Highcharts 10.0.0COVID-19D-dimerlevelsseveritypatientsGabonseverestudyanalysisdiseaseincreasedriskoutcomesElevatedtherapyelevatedclinicalincludedcostsmultivariableadjustedoddsORage333costBACKGROUND:Coronavirus2019stronglyassociatedthromboticeventsincludingpulmonaryembolismcriticalbiomarkerassessingearlyimplementationanticoagulationtestingcrucialmanaginghypothesizeslinkedAIM:determineimpactroleguidingdecisionsMETHODS:retrospectiveanalyzedadmittedtwohospitalsMarch2020December2023confirmeddiagnosesavailablemeasurementsadmissionDatademographicshealthcarecollectedclassifiednon-severeoutpatientsinpatientslogisticregressionmodelusedassessrelationshipratios95%CIRESULTS:total3004mean5017yearsmajorityfemale5343%found6581%5721%experiencedUnivariateshowedtimeshigher=95%CI:284-392<0001associationremainedsignificantsexyearcollectionfinancialrevealedsubstantialburdenparticularlyuninsuredCONCLUSION:predictsguidestreatmenthighanticoagulanthighlightsneedpoliciesensuringaffordableaccessresource-limitedsettingslikeInterestlevelmanagementD-dimersDiseaseHealthcareManagement

Similar Articles

Cited By